Effects of ubenimex adjuvant chemotherapy on adverse reactions, quality of life, inflammatory cytokines and immune function in patients with breast cancer / 中国基层医药

ABSTRACT

Objective:To observe the effects of ubenimex adjuvant chemotherapy on adverse reactions, quality of life, inflammatory cytokines and immune function in patients with breast cancer.Methods:A total of 102 breast cancer patients treated in Hangzhou Cancer Hospital from January 2016 to December 2018 were selected in the research, and they were divided into observation group and control group according to the random number table method, with 51 cases in each group.The control group was given chemotherapy alone, and the observation group was treated with ubenimex on the basis of the control group.The short-term clinical efficacy, immune function indicators (CD 3+, CD 4+, CD 8+, CD 4+/CD 8+), serum inflammatory factors[interleukin-10 (IL-10), tumor necrosis factor α (TNF-α), C-reactive protein (CRP)] and quality of life[Quality of Life Questionnaire-Core 30 (QLQ-C30)] before treatment and after 3 months of treatment were compared between the two groups, and the occurrence of adverse reactions were recorded during treatment. Results:After treatment, the total effective rate in the observation group was higher than that in the control group (64.71% vs.45.10%) (χ 2=3.960, P<0.05). After 3 months of treatment, the CD 3+, CD 4+ and CD 4+/CD 8+ levels in the observation group were significantly higher than those before treatment[(60.26±3.18)%, (43.17±2.35)%, (1.59±0.11) vs.(52.25±3.15)%, (37.36±4.24)%, (1.11±0.19)]( t=18.074, 12.592, 22.853, all P<0.05), which were significantly higher than those in the control group [(46.58±2.19)%, (33.26±2.28)%, (0.99±0.10)] ( t=25.302, 21.614, 28.823, all P<0.05). The CD 8+ level in the observation group was significantly lower than that before treatment[(27.16±2.14)% vs.(33.59±2.54)%]( t=19.624, P<0.05), which was significantly lower than that in the control group [(33.57±2.24)%] ( t=14.776, P<0.05). The CD 3+, CD 4+ and CD 4+/CD 8+ levels in the control group were significantly lower than those before treatment[(46.58±2.19)%, (33.26±2.28)%, (0.99±0.10) vs.(52.25±3.34)%, (37.16±3.09)%, (1.11±0.12)]( t=14.644, 10.373, 7.791, all P<0.05), and there was no statistically significant difference in the CD 8+ level compared with before treatment[(33.57±2.24)% vs.(33.49±2.19)%]( P>0.05). After 3 months of treatment, the IL-10 level in the observation group was significantly higher than that before treatment[(7.85±1.08)pg/L vs.(5.26±1.48)pg/L]( t=14.450, P<0.05), while the TNF-α and CRP levels were significantly lower than those before treatment[(5.26±1.59)ng/L, (9.63±1.55)mg/L vs.(10.16±2.12)ng/L, (43.26±6.06)mg/L] ( t=18.864, 63.119, all P<0.05), but there were no statistically significant differences in the levels of IL-10, TNF-α and CRP in control group compared with before treatment[(5.26±1.34)pg/L, (9.58±2.49)ng/L, (44.58±7.76)mg/L vs.(5.16±1.59)pg/L, (10.06±2.65)ng/L, (43.07±6.09)mg/L]( t=0.487, 1.334, 1.557, all P>0.05). After 3 months of treatment, the scores of physical function, role function, emotional function, cognitive function and social function in the observation group were significantly higher than those before treatment[(70.46±7.42)points, (74.97±7.55)points, (72.13±8.25)points, (63.43±6.75)points, (69.24±5.91)points vs.(50.42±7.95)points, (55.14±6.31)points, (55.15±7.31)points, (48.21±8.33)points, (48.55±5.73)points]( t=18.623, 20.435, 15.586, 14.415, 21.440, all P<0.05), and the above scores in the control group were significantly higher than those before treatment[(63.17±7.01)points, (67.10±7.22)points, (64.41±7.95)points, (52.93±8.14)points, (60.51±8.34)points vs.(51.43±6.65)points, (55.34±6.66)points, (55.15±7.64)points, (49.13±8.41)points, (47.13±7.45)points]( t=12.275, 12.101, 8.484, 3.279, 12.103, all P<0.05), and the scores in the observation group were significantly higher than those in the control group ( t=5.100, 5.380, 4.812, 7.091, 6.099, all P<0.05). The total incidence of adverse reactions in the observation group was significantly lower than that in the control group (11.76% vs.35.29%) (χ 2=7.846, P<0.05). Conclusion:Adjuvant chemotherapy with ubenimex can significantly improve the immune function of breast cancer patients, enhance the quality of life, and can significantly reduce the levels of inflammatory factors and adverse reactions during chemotherapy, and it is safe and effective.